Medipharm Labs Corp T.LABS

alleyesonme.....Pfizer ROFR...

[subaru1i]

Your analysis of an unsollicited take over offer does not suprise me at all with LABS being the only FDA and Health Canada (dual country approvals) for pharmaceutical cannabinoid molecules. 

BUT.....with over 20 strong clinical trials (LABS balance sheet does not reflect over $100 million in debt to fund them) and a ' large traditional global pharmaceutical PARTNER, there could be an agreement between them...I am thinking an ROFR or 'right of first refusal'.   

I think Pfizer has the ROFR...

avg cost of a clinical trial runs between $4.6 to $25.8 million CAD....bang that out by 20 strong clinical trials and then reference the LABS balance with only $3 million in debt, nicely reminded by CEO Pidduck at the recent CC.

SO WHO FUNDED ALL OF THOSE 20+ clincial trials and I am not talking about the recent single NIH clinical trial either

• The ROFR assures the holder that they will not lose their rights to an asset if others express interest.